

Improving access to diabetes care in Ghana

Sanofi is strengthening its commitment to improving access to prevention, treatment and care for people living with diabetes in LMICs and underserved communities

Sanofi has signed its first partnership with Ghana Ministry Of Health. The program of this partnership includes:

High-quality analog insulins at an affordable price

Patient disease awareness

HCP capacity building, diabetes management and digital solutions



We are aiming to impact the lives of *190,000 people* living in LMICs with either Type 1 or Type 2 diabetes within 5 years

Enterogermina®¹ – “Bellies ready!” 7 quarters of market share gain

#1 Probiotic brand worldwide²

Born in Italy
in 1958

now
marketed in
55 countries

Expanded from
kid’s tummy
recovery post
antibiotic use

to adult
and wellbeing

A brand linked to a purpose

- › Engaging consumers in our ambition to *prevent childhood mortality from diarrhea*
- › *1 million beneficiaries* through our programs from 2019 to 2025



1. Contains Bacillus clausii or other probiotics. 2. Based on total retail sales of the OTC market, excl. China, incl. ~50% of the eCom channel (data provided by various vendors, e.g. IQVIA, Nielsen, IRI, Intage, and compiled by Sanofi).

sanofi



ESG
appendices



Sanofi ESG Q1 *achievements*

Affordable access



Sanofi Global Health Unit

#Patients treated

Q1 2022	Q1 2023
NCD 46,300 12 countries	NCD 54,396 19 countries ●
Tuberculosis 35,094	Tuberculosis 3,022 ▼
Malaria 1,024,170	Malaria 2,725,117 ●


Rare disease vials donation

Q1 2022	Q1 2023
998 patients treated	1,065 patients treated
22,682 vials donated	21,542 vials donated ●

Global access plan

Q4 2022	Q1 2023
Global access plan initiated for 2 assets	6 global access plans initiated or developed covering more than 10 indications ●

R&D for unmet needs



Polio eradication

Q1 2022	Q1 2023
16 million IPV doses supplied to UNICEF	7 million IPV doses supplied to UNICEF ▼

Sleeping sickness elimination

FY 2021 ¹	FY 2022
2 million patients tested for HAT	Data updated annually at Q2 23
805 patients treated	●

Pediatric cancer treatment development

Q4 2022	Q1 2023
1 asset pre-clinical assessment complete	2 assets in protocol preparation for clinical study ●
1 asset in protocol preparation for clinical study	
1 additional asset identified for clinical development	

Data in YTD unless stated otherwise. 1. Data provided by WHO.

Sanofi ESG Q1 *achievements*

Planet care



Blister-free syringe vaccines

FY 2022	FY 2023
33% of blister free syringe vaccines produced	Data updated annually at Q4 23

Eco-design

Q4 2022	Q1 2023
7 LCAs completed & 1 in progress ¹ Eco-design digital solution launched	7 LCAs completed & 4 in progress (new products and marketed product) ¹

Scope 1 & 2 GHG emissions reduction

Q4 2022	Q1 2023
-29.4% vs 2019	-30.5% vs 2019

Renewable electricity & eco-car fleet

Q4 2022	Q1 2023
62% renewable electricity	62.6% renewable electricity
34.1% eco-fleet	34.9% eco-fleet

In and beyond the workplace



Diverse Senior Leadership

Q4 2022	Q1 2023
37.2% of our executives and 41.7% of our senior leaders were women	37.5% of our executives and 42.1% of our senior leaders were women

Engagement with communities

Q4 2022	Q1 2023
4,975 volunteers	Next update in Q2 2023
26,906 hours	

From Leaders to Citizens

Q4 2022	Q1 2023
More than half of the leaders have completed the initial eLearning phase	65% of the leaders have completed the eLearning phase
	9% of the leaders have completed the full program

Data in YTD unless stated otherwise. 1. Since 2019.

Sanofi ESG ratings

Rating agencies



SCORE								
86/100	21.5 Medium risk	71/100	A	Climate Change: A Water: A-	B	4.3/5	3.47/5	64/100
New rating done in 2022	▼ 21.2	▲ 70/100	= A	= ▼ A/A	= B	▲ 4.2/5	= 3.47/5	▲ 62/100
One of the highest scores across all sectors globally 80 points for its solid fundamentals & strong preparedness opinion of 6 points	11 th among 433 pharmaceutical companies	Percentile of 97 within 156 scored companies in the industry	Within the top 6 highest rated pharmaceutical companies	Leading position	1 st decile of the 476 companies in the industry	With very high rating across the 3 pillars ESG	Top 10 company	1 st pharmaceutical company out of 57 Score in progress since 2018



Vs previous rating

Scores assigned by the rating agencies are not equivalent.